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esponsibility of Xi'aAbstract A simple, precise, accurate stability-indicating gradient reversed-phase high-performance liquid
chromatographic (RP–HPLC) method was developed for the quantitative determination of zotepine (ZTP) in
bulk and pharmaceutical dosage forms in the presence of its degradation products (DPs). The method was
developed using Phenomenex C18 column (250 mm 4.6 mm i.d., 5 mm) with a mobile phase containing a
gradient mixture of solvents, A (0.05% triﬂuoroacetic acid (TFA), pH¼3.0) and B (acetonitrile). The eluted
compounds were monitored at 254 nm; the run time was within 20.0 min, in which ZTP and its DPs were well
separated, with a resolution of41.5. The stress testing of ZTP was carried out under acidic, alkaline, neutral
hydrolysis, oxidative, photolytic and thermal stress conditions. ZTP was found to degrade signiﬁcantly in
acidic, photolytic, thermal and oxidative stress conditions and remain stable in basic and neutral conditions.
The developed method was validated with respect to speciﬁcity, linearity, limit of detection, limit of
quantiﬁcation, accuracy, precision and robustness as per ICH guidelines. This method was also suitable for the
assay determination of ZTP in pharmaceutical dosage forms. The DPs were characterized by LC–MS/MS and
their fragmentation pathways were proposed.
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The parent drug stability test guidelines Q1A (R2) issued by
International Conference on Harmonization (ICH) [1–4] requires the
stress stability studies to be done on a drug to establish its inherent
stability characteristics. This helps to identify the likely degradation
pathways and degradation products (DPs) of the drug. It is a
prerequisite that analytical test procedures should be stability indicat-
ing and fully validated. Accordingly, the aim of the present study was
to establish inherent stability of zotepine (ZTP) and to develop a
stability-indicating assay method through stress studies under a variety
of ICH recommended test conditions [1,5–8]. The chemical name ofier B.V. All rights reserved.
M.V.N. Kumar Talluri et al.108ZTP is 2-((8-chlorodibenzo[b,f]thiepin-10-yl)oxy)-N,N-dimethyletha-
namine (Fig. 1). It is an atypical antipsychotic drug which is
highly effective in acute exacerbation of schizophrenia. It has
fewer adverse effects than conventional antipsychotics [9].
Green et al. [10] reviewed research studies on ZTP and its
adverse reactions related to metabolic effects and movement
disorders. A thorough literature search revealed that few LC and
LC–MS methods are available for determination of ZTP in
plasma, serum and other biological matrices [11–13]. A liquid
chromatography quadrupole time-of-ﬂight mass spectrometry
(LC–QTOF–MS) method was reported for the analysis of ZTP
in 77 blood samples [14]. Nozaki et al. [15] investigated the
electrochemical oxidation behavior of ZTP and its fragmenta-
tion using electrospray ionization–mass spectrometry (ESI–MS)
coupled with a microﬂow electrolytic cell. Capillary electro-
phoresis method was reported for determination of ZTP and its
metabolite in human plasma [16]. GC and GC–MS methods
were also reported for quantiﬁcation of ZTP in bioﬂuids
[9,17,18]. As there are no reports available on the degradation
behavior, identiﬁcation and characterization of DPs of ZTP
formed under various stress conditions, the present work has
been undertaken on development of an HPLC-UV stability
indicating assay method for separation and determination of
ZTP in the presence of DPs and characterization of degradants
by using LC–QTOF–MS.Table 1 The optimized gradient elution program for ZTP
and its DPs.2. Experimental
2.1. Materials and stability equipments
ZTP was obtained as a gift sample by Symed Laboratory Limited,
Hyderabad, India. Acetonitrile (HPLC grade) was purchased from
Merck (Lichrospher, Darmstadt, Germany). Water was puriﬁed by
using a Milli-Q Gradient ultrapure water system (Billerica, MA 01821,
USA). Analytical reagent grade triﬂuoroacetic acid (TFA), hydrochloric
acid (HCl), sodium hydroxide (NaOH), and hydrogen peroxide (H2O2)
used in the present study were purchased from S.D Fine chemicals
(Mumbai, India). Photo stability studies were carried out in a
OSWORLD (model JRIC-11C) photo stability chamber with humidity
and temperature control. The chamber was equipped with an
illumination bank made of light sources, viz., a cool white ﬂuorescent
lamp designed for emitting signiﬁcant radiation same as that speciﬁed
in ISO 10977 (1993) 320 nm and a near UV ﬂuorescent lamp with a
maximum energy emission between 350 nm and 370 nm [19] for
providing an overall illumination of not less than 1.2 million lux hours
and irradiation density of not less than 200 W/m2. Thermal stability
studies were performed in a dry air oven (Osworld Scientiﬁc
Equipments Pvt. Ltd., Mumbai, India).S
O
Cl
N
Fig. 1 Chemical structure of zotepine.2.2. Instrumentation
The analysis was carried out using an Agilent 1200 series HPLC
instrument (Agilent Technologies, USA) coupled to a quadrupole
time-of-ﬂight (Q-TOF) mass spectrometer (Q-TOF LC/MS 6510
series classic G6510A, Agilent Technologies, USA) equipped with
an ESI source. The data acquisition was under the control of Mass
Hunter workstation software. The chromatographic data were
recorded using a computer system with chemstation data acquiring
software. The HPLC-UV data were used for quantitative determi-
nation of ZTP and the same chromatographic conditions were
used for mass spectral identiﬁcation and characterization of its
degradants.
2.3. LC–MS conditions
The chromatographic separations were carried out on a reversed-
phase Phenomenex Luna C18 (250 mm 4.6 mm i.d.) column
with particle size of 5 μm (Phenomenex, Hyderabad, India) and the
column was maintained at an ambient temperature (30 1C). HPLC
separation was achieved with gradient elution (Table 1) using
0.05% TFA buffer (pH adjusted to 3.0), and acetonitrile as mobile
phase. The mobile phase was ﬁltered through 0.45 mm nylon
membrane and degassed by using an ultra sonicator before use.
The injection volume was 20 mL and the mobile phase ﬂow rate
was at 1 mL/min. A splitter was placed before the ESI source,
allowing entry of only 35% of the eluent. The typical operating
source conditions for MS scan of ZTP in positive ESI mode were
optimized as follows: the fragmentor voltage was set at 80 V; the
capillary at 3000 V; the skimmer at 60 V; nitrogen was used
as the drying (300 1C; 9 L/min) and nebulizing (45 psi) gas.
Ultra high pure nitrogen was used as collision gas. All the spectra
were recorded under identical experimental conditions, and are an
average of 25 scans.
2.4. Stress degradation studies
All stress decomposition studies were performed with an initial
drug concentration of 1 mg/mL in methanol and water (8:2). Acid
hydrolysis was performed in 1 M HCl at room temperature for
18 h. The study in alkaline condition was carried out in 5 M NaOH
at 70 1C for 5 days under reﬂux. For neutral degradation study, the
drug was dissolved in a mixture of methanol and water (8:2) and
was heated at 60 1C for 7 days under reﬂux. Oxidative studiesTime (min) Mobile phase
A (%) B (%)
0.01 75 25
2.50 50 50
10.0 40 60
12.5 0 100
20.0 0 100
22.5 75 25
30.0 75 25
A: 0.05%TFA (triﬂuoroacetic acid, pH 3); B: acetonitrile.
Table 4 HPLC analysis results of zotepine in SIRILEPTs Tablets.
S. no. Zotepine labeled amount (mg) Measureda amount 7SD (mg) Mean recovery (%) (RSD%)
1 Batch 1: 50 49.9770.17 99.93 (0.34)
2 Batch 2: 50 49.2370.12 98.47 (0.25)
3 Batch 3: 50 50.2770.17 100.53 (0.34)
aAverage of three determinations.
Table 3 Recovery data of ZTP by RP–HPLC.
Amount added (mg/mL) Mean of amount found (mg/mL, n¼3) Recovery (amount found/added 100) SD RSD (%)
25 25.33 101.33 0.21 0.81
100 99.83 99.83 0.21 0.21
150 150.03 100.02 0.17 0.11
200 199.63 99.82 0.42 0.21
250 250.00 100.00 0.80 0.32
Table 2 System suitability data of zotepine and its DPs.
Drug/DPs Retention time (Rt) Resolution (Rs) Tailing factor (Tf) Capacity factor (k
1) [M+H]+ ions (m/z)
ZTP 9.5 – 1.20 – 332.0
Z1 9.9 1.95 1.32 0.04 348.0
Z2 14.0 18.0 1.10 0.56 318.0
Z3 18.8 22.0 1.02 1.09 261.0
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Degradation was also carried out in solid state by exposing pure
drugs to dry heat at 70 1C for 2 weeks, and in photo stability
chambers for 6 h. Samples were withdrawn periodically and
subjected to immediate analysis after suitable dilution.
2.5. Sample preparation
Acid and base hydrolyzed samples were neutralized with NaOH
and HCl, respectively. The samples were further diluted to 10
times. Other products of degradation viz., thermal, photolysis,
oxidation and neutral hydrolysis were also diluted to 10 times from
their initial concentration. All the samples were ﬁltered through
0.22 mm membrane ﬁlter before HPLC and LC–MS analysis.
3. Results and discussion
3.1. HPLC method development and optimization
For optimization of chromatographic conditions using C18 column,
various buffers such as KH2PO4 (10 mM, pH 3–5) were tried. Since
ZTP is a polar compound, it was eluted early in most of the
conditions. We have avoided further usage of phosphate buffer as it
is non-volatile and unamenable with MS detector. Ammonium
acetate buffer (10 mM, pH adjusted to 3.5 with CH3COOH) with
organic modiﬁers, viz. methanol and acetonitrile (ACN) was tried. It
was observed that ACN was found to be better in terms of
resolution and peak shapes as compared to methanol. ACN has
higher elution strength and the early retention times were achievedwith less percentage than methanol. TFA, an ion-pairing reagent as
mobile phase additive was used for the separation of ZTP from its
degradants on C18 column because TFA provides better separation
of basic analytes from other components in the sample [20]. TFA
can be used as a mobile phase pH stabilizer and as an effective ion-
pair reagent to control retention and selective separation of small
ionizable compounds by RP–HPLC. Of the various percentages of
TFA (0.05%, 1% and 2%), 0.05% was found to be highly suitable
for better separation of the chromatographic peaks of all the analytes
from each other with symmetrical peak shapes. Further studies were
carried out on the pH effect of the buffer (0.05% TFA, pH 3, 4 and
5) on retention times, resolution and peak tailing. The symmetrical
peaks were observed at pH 3 with improved resolutions. In addition,
the gradient analysis, in which the strength of the mobile phase
increased with time during sample elution, was suited for complex
samples containing analytes of wide polarities and better separation
[21]. At an initial content of 5% of ACN in mobile phase, ZTP was
not eluted even after 15 min. When it was increased to 25%, ZTP
eluted at 9.5 min. It was further tried to decrease the retention time
by increasing ACN percentage but zotepine S-oxide (Z1) was co-
eluted with ZTP due to similar polarity. Therefore the initial ACN
was kept constant at 25% and the required resolution 1.95 was
achieved for Z1. The mobile phase was used at a ﬂow rate of 1 mL/
min and the injection volume was 20 mL. The TFA (0.05%, pH 3)
and ACN mobile phases were optimized with gradient elution mode
since the degradants possessed varying polarities. Thus the peak
shapes (Tfo1.3) and resolutions (41.95) were further improved.
The method was amenable for high-throughput screening of ZTP
and for characterization of its degradants.
Table 5 Intra-day and inter-day data of ZTP.
Assay Amount added (mg/mL)
25.00 100.00 150.00 200.00 250.00
Intra-day assay
Day 1
Mean conc. (mg/mL, n¼3) 25.27 99.87 150.07 199.87 250.27
SD 0.17 0.29 0.12 0.17 0.12
RSD (%) 0.67 0.29 0.08 0.09 0.05
Day 2
Mean conc. (mg/mL, n¼3) 25.43 99.87 149.97 199.90 249.60
SD 0.12 0.21 0.26 0.24 0.57
RSD (%) 0.49 0.21 0.18 0.12 0.23
Day 3
Mean conc. (mg/mL, n¼3) 25.20 100.20 150.30 200.40 249.60
SD 0.08 0.08 0.16 0.29 0.57
RSD (%) 0.32 0.08 0.11 0.15 0.23
Inter-day assay
Mean conc. (mg/mL, n¼3) 25.50 100.50 150.63 200.50 250.63
SD 0.16 0.16 0.25 0.16 0.25
RSD(%) 0.64 0.16 0.17 0.08 0.10
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3.2.1. Linearity, LOD and LOQ
Linearity test solutions were prepared from stock solution at eight
concentration levels of analyte (0.1, 1, 10, 25, 50, 100, 150, 250 mg/
mL). The peak area versus concentration data is performed by least
squares linear regression analysis. The calibration curve was drawn by
plotting average areas for triplicate injections of ZTP versus the
concentrations in µg/mL. Linearity was checked over the same
concentration range for three consecutive days. Good linearity was
observed in the concentration range from 0.1 to 250 mg/mL of ZTP.
The data were subjected to statistical analysis using a linear regression
model; the linear regression equation and correlation coefﬁcient
(r2) were y¼56,227.6 (769.59)x+86,403 (7737.40, tcalculated:
0.50ottheoretical: 3.18) and40.9997, respectively. These results indicate
a good linearity. The limits of detection (LOD) and quantiﬁcation
(LOQ) represent the concentration of the analyte that would yield a
signal-to-noise ratio of 3 for LOD and 10 for LOQ[22,23]. The LOD
and LOQ values were found to be 0.03 and 0.10 mg/mL, respectively.
3.2.2. Speciﬁcity
Speciﬁcity is the ability of the analytical method to measure the
analyte concentration accurately in the presence of all potential
DPs. The speciﬁcity was determined by subjecting ZTP to stress
degradation under various stress conditions. All the DPs were well
separated with good resolution (Table 2).
3.2.3. Accuracy (recovery) and precision
The recovery of ZTP was determined by spiking to the placebo
sample at ﬁve different concentration levels i.e., 25, 100, 150, 200,
250 mg/mL each in triplicate. The recovery was determined by the
following equation: recovery¼amount found/amount taken 100.
The percentage recovery range and RSD values were found to be
99.0–101 and o1% respectively (Table 3). This method was
applied to ZTP tablets and observed results were comparable with
label claim of the formulations with an accuracy range of 98.4–
100.5% and RSD values are found to be less than 1.0% (Table 4).
The precision in determination of the assay was studied by
repeatability, intermediate precision and reproducibility(ruggedness). Repeatability is the intra-day variation in assay
obtained at different concentration levels of ZTP expressed in terms
of RSD calculated for each day. Values were found to be below
1.0% indicating a good repeatability (Table 5). The intermediate
precision is the inter-day variation at the same concentration level
determined on successive days. The inter-day variations calculated
for ﬁve concentrations levels from above data of 3 days are
expressed in terms of %RSD values. At each concentration level,
the RSD values were below 1.0%, indicating a good intermediate
precision. The ruggedness of the method is deﬁned as the degree of
reproducibility obtained by analysis of the same sample under a
variety of conditions at different labs, with different analysts,
instruments and lots of reagents. The same samples of three
concentrations were analyzed in triplicate on 2 days by another
instrument (LC-20A Module HPLC, Shimadzu system containing
two pumps and a UV detector) by a different analyst with different
lots of reagents and columns. The data obtained were within 1%
RSD.
3.3. Degradation of ZTP
The degradation behavior of ZTP under various stress conditions was
investigated using HPLC. Typical chromatograms are shown in Fig. 2.
Accurate knowledge regarding the relative response factors (RRF) of
the degradants is vital for peak area mass-balancing during stability
studies. A recent study on the degradation of β-artemether [24] reported
a new approach for pharmaceutical stress conditions by using Matlab
software mathematical model. This approach provided a good model ﬁt
with good correlation between the calculated and experimental residual
mass of β-artemether. This approach may be ideal to calculate the RRF
of degradants for mass balancing during stability studies of pharma-
ceuticals like β-artemether. However, the present study is not focused
on the RRF calculations for mass balance of the ZTP stability study.
3.3.1. Hydrolysis
Initially ZTP was reﬂuxed in 0.01 and 0.1 M HCl for 1 week, but no
degradation was observed. When the strength of the acid was
increased to 1 M HCl, 30% degradation was observed in 24 h. One
degradation product was formed on acid hydrolysis, which was coded
Fig. 2 Typical HPLC chromatograms of (A) ZTP std, (B) acid hydrolysis, (C) base hydrolysis, (D) neutral hydrolysis, (E) oxidation, (F) photolytic
and (G) thermal conditions.
LC–MS/MS separation, characterization of zotepine degradants 111as Z3 and eluted with Rt of 18.8 min. No degradation occurred for 7
days in neutral condition upon heating the sample solution in methanol
and water (80:20) at 60 1C. ZTP was reﬂuxed in (1–5 M) NaOH at
60 1C for 7 days. But no degradation was observed and the drug was
found to be highly stable in both neutral and alkaline hydrolysis.3.3.2. Oxidative conditions
The drug was found to be highly labile in oxidative degradation
conditions. The reaction in 3% hydrogen peroxide at room
temperature was so fast that within 45 min the drug degraded to
the extent of 23.2% and 100% in 4 h. Subsequently, studies were
performed in low concentration. With 1% hydrogen peroxide
solution at room temperature, degradation was observed to theextent of 5.8% and 10% in 1 h and 3 h, respectively and the
degradation product (DP) was coded as Z1 and eluted at 9.9 min.
3.3.3. Photolytic conditions
The solid form of the drug was stable on exposure to a cool white
ﬂuorescent lamp emitting signiﬁcant radiation below 320 nm and
0.1% degradation was observed after 72 h exposure. However,
25% degradation was observed in solution form within 3 h, and
2.3% degradation was observed in 8 h when it was exposed to
direct sunlight and the DP (Z3) was eluted at 18.8 min.
3.3.4. Thermal conditions
The drug was found to be stable under thermal degradation
conditions. Degradation was carried out in solid form by exposing
Fig. 3 LC–ESI–MS/MS spectra of (A) [M+H]+ ions (m/z 332) of ZTP at 15 eV, (B) [M+H]+ ions (m/z 348) of Z1 at 15 eV, (C) [M+H]+ ions
(m/z 318) of Z2 at 15 eV and (D) [M+H]+ ions (m/z 261) of Z3 at 15 eV.
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Table 6 Elemental compositions for protonated ZTP, degradation products Z1–Z3 and their product ions.
Drug/degradant Molecular formula Observed mass (Da) Calculated mass (Da) Error (ppm) Neutral loss Rt (min)
ZTP ([M+H]+) C18H19ClNOS
+ 332.0878 332.0870 −1.81 – 9.5
Product ions
C18H17ClNS
+ 314.0761 314.0765 2.31 H2O
C16H12ClOS
+ 287.0299 287.0292 −4.81 C2H7N
C15H12ClS
+ 259.0349 259.0343 −3.16 CO
C14H10ClS
+ 245.0180 245.0186 2.62 C2H2O
C14H9S
+ 209.0411 209.0419 3.61 HCl
Z1 ([M+H]+) C18H19ClNO2S
+ 348.0828 348.0820 −2.61 – 9.9
Product ions
C18H19ClNO
+ 300.1149 300.1150 1.16 SO
C14H12ClO
+ 231.0588 231.0571 −4.61 C4H7N
C4H10ON
+ 88.0751 88.0757 2.16 C14H9OSCl
C4H10N
+ 72.0811 72.0808 −3.12 C14H9ClO2S
C3H8N
+ 58.0650 58.0651 0.98 C15H11ClO2S
Z2 ([M+H]+) C17H17ClNOS
+ 318.0711 318.0714 2.61 – 14.0
Product ions
C17H14ClOS
+ 301.0450 301.0448 −2.68 NH3
C13H14NOS
+ 232.0798 232.0791 −3.16 C4H3Cl
C12H8ClS
+ 219.0028 219.0030 3.26 C5H6NO
C13H12NO
+ 198.1911 198.0913 1.18 H2S
C6H6S
+ 111.0625 110.185 2.61 C11H10NOCl
C3H6NO
+ 72.0438 72.0444 4.98 C14H11ClS
C3H8N
+ 58.0646 58.0651 3.16 C14H9ClOS
Z3 ([M+H]+) C14H10ClOS
+ 261.0138 261.0135 −2.61 – 18.8
Product ions
C13H8ClS
+ 231.0031 231.0030 −1.01 CH2O
C14H9OS
+ 225.0359 225.0369 4.16 HCl
C13H6Cl
+ 197.0150 197.0153 1.16 H2S
C7H8Cl
+ 127.0311 127.0309 −3.16 C7H2OS
C7H7
+ 91.0540 91.0542 1.16 C7H3ClOS
C4H2Cl
+ 84.9918 84.9840 −6.16 C10H8OS
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observed. The drug was degraded at 70 1C temperature in 2 weeks
time and only 3% thermal DP (Z2) was eluted at 14.0 min.
3.4. Assay of zotepine in tablet formulations
Twenty tablets are weighed and crushed in motor, the powder
equivalent to 50 mg of ZTP was weighed and dissolved in MeOH:
water (50:50) then it was sonicated, ﬁltered and two series of
dilutions are made in mobile phase to get a concentration of
100 μg/mL. These samples were subjected to HPLC analysis and
the measured values were compared to those of labels (Table 4).
3.5. Characterization of ZTP and its degradation products by
LC–MS/MS
ZTP and other tricyclic class of pharmaceutical compounds have
long been used for the treatment of mental disorders such as
schizophrenia. Chlorpromazine and trimipramine contains carbon
chains ending with a tertiary nitrogen atom, –(N–CH2–CH2–CH2–
N (CH3)2) and –(N–CH2–CHCH3)–CH2–N(CH3)2), respectively.
Smyth et al. [25] have established rules of fragmentation for such
drugs with a carbon chain ending in a tertiary nitrogen atom with
at least two methylene groups. These drugs eliminate the end
nitrogen atom as the corresponding secondary amine in both in-
source fragmentation (MS) and MS2 mode. The deaminated ions
lose the corresponding alkene from these two methylenes or
substituted methylene groups. Chlorpromazine and Lignocaine
yield a characteristic peak at m/z 86 due to CH2QCH–
CH2NH
+(CH3)2 and CH2QN
+(C2H5)2, respectively. Flurazepamwith side chain –N–CH2–CH2–N (C2H5)2 yields a peak at m/z 73
due to loss of –NH (C2H5)2 from the end-of chain. The
phenothiazine and promethazine, with side chain –N–CH2–CH
(CH3)–N(CH3)2, fragments at the C–C bond yielding a base peak
at m/z 72 due to CH3CHQN
+(CH3)2. Chlorpromazine and
trimeprazine also yield a signal at m/z 45 due to loss of
(CH3)2NH from the end of chain. Promazine, with side chain –
N–CH2–CH2–CH2–N (CH3)2, fragments extensively to yield
major signals at m/z 86 and 58 (base peak) [26]. These diagnostic
peaks of low m/z values are observed in the EI-MS of
phenothiazines, acepromzine and propionylpromazine which
contain side chains with an amino group [27]. The electrospray
ionization of pharmaceutically important 1, 4-benzodiazepines
and their subsequent fragmentations were reported [28]. 1,
4-benzodiazepines generally eliminate 29u and 28u due to loss
of COH and CO groups, respectively. This involves, ring
contraction of seven membered heterocyclic rings to six mem-
bered rings [29]. The [M+H]+ of amphetamine loses NH3 by
charge site initiated fragmentation with H atom transfer resulting
in the corresponding alkene [30]. These studies on ESI-MS
behavior of structurally similar drugs were helpful for interpreta-
tion of proposed structure of ZTP degradants.3.5.1. MS/MS collision-induced dissociation (CID) of ZTP
The positive ion ESI-MS of ZTP shows a highly abundant [M
+H]+ and low abundance [M+Na]+ ions. The CID spectrum
(Fig. 3A) of protonated ZTP yields abundant product ions at m/z
287 (loss of N,N-dimethyl amine), m/z 259 (loss of CO from m/z
287), m/z 245 (loss of ketene from m/z 287) (base peak), m/z 209
(loss of HCl from m/z 245) and a low abundance ion at m/z 314
SO
N
Cl
m/z 348 m/ z 88
m/z 58
m/z 72
N
N
O
O
N
Cl Cl
OH
m/z 300
m/z 231
N O
H
H
H
H
H
-SO
-C4H7N
Scheme 3 Proposed fragmentation mechanism for degradation
product Z1(m/z 348).
Scheme 4 Proposed fragmentation mechanism for degradation
product Z2 (m/z 318).
Scheme 1 Proposed fragmentation mechanism for protonated ZTP
(m/z 332).
Scheme 2 Proposed structures of DPs (Z1–Z3) formed under
various stress conditions.
M.V.N. Kumar Talluri et al.114(loss of H2O) (Scheme 1). All these fragmentation pathways have
been conﬁrmed by accurate mass measurements (Table 6).
3.5.2. MS/MS CID of degradation products (DPs)
The three DPs, Z1–Z3 were eluted within 20 min on C-18 column.
The proposed structures of all the DPs with retention times are
shown in Scheme 2 and Table 2. These structures have been
further supported by LC-ESI-MS/MS experiments with accurate
mass measurements of all the protonated DPs and their fragment
ions (Table 6).
3.5.2.1. Z1 ([M+H]+, m/z 348). The LC-ESI-MS/MS spectrum
of [M+H]+ions (m/z 348) of Z1 (Rt¼9.9 min, oxidative degrada-
tion product), shows product ions at m/z 300 (loss of SO), m/z 231
(loss of N,N-dimethyl ethyl amine from m/z 300), m/z 88
(protonated 2-(dimethyl amino) acetaldehyde), m/z 72 (protonated
N,N-dimethylethenamine) and m/z 58 (N-methyl-N-methylene-
methanaminium) (Scheme 3, Fig. 3B). All these fragmentation
pathways have been conﬁrmed by accurate mass measurements
(Table 6). As it can be seen from Scheme 3, the fragmentation
pattern of protonated Z1 is highly consistent with its proposedstructure, 2-(8-chlorobenzo[b][1]benzothiepin-6-yl)oxy-N,N-dime
thyl ethanamine-s-oxide. Zotepine-N-oxide [31] was not observed
under optimized stress conditions and it may be formed during
long storage conditions of liquid formulations [32].3.5.2.2. Z2 ([M+H]+, m/z 318). The LC-ESI-MS/MS spectrum
of [M+H]+ions (m/z 318) of Z2 (Rt¼14.0 min), which was
observed under thermal degradation conditions, shows product
ions at m/z 301 (loss of NH3), m/z 232 (loss of C4H3Cl), m/z 198
(loss of H2S from m/z 232), m/z 219 (loss of C5H9NO from m/z
318), m/z 72 (protonated 2-(methyl amino) ethenone), m/z 58
(protonated N-methyl ethenamine) (Fig. 3C). The fragmentation
pathways have been conﬁrmed by accurate mass measurements
(Scheme 4 and Table 6). Based on MS/MS and accurate mass
measurements, Z2 was identiﬁed as 2-(8-chlorobenzo[b][1]ben-
zothiepin-6-yl)oxy-N-methyl ethanamine cation.
SO
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C Cl
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OH
m/z 225
m/ z 197
H
H
-H2S
H
H2C
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Scheme 5 Proposed fragmentation mechanism for degradation product Z3 (m/z 261).
LC–MS/MS separation, characterization of zotepine degradants 1153.5.2.3. Z3 ([M+H]+, m/z 261). Fig. 3D shows the LC–ESI–MS/
MS spectrum of [M+H]+ions (m/z 261) of Z3 (Rt 18.8 min),
which was observed under acidic and photolytic conditions. The
spectrum displays abundant product ions at m/z 231 (loss of
HCHO), m/z 197 (loss of H2S from m/z 231) and low abundance
ions at m/z 225 (loss of HCl from m/z 261), m/z 127 (protonated 1-
chloro-3-methylbenzene), m/z 91 (C7H7
+), and m/z 85
(2-chlorocyclobuta-1, 3-dien-1-ylium) (Scheme 5). The MS/MS
experiments combined with accurate mass measurements (Table 6)
have conﬁrmed the proposed structures. All these data are highly
compatible with the proposed structure (8-chlorodibenzo [b,f]
thiepin-10-yl) oxonium for Z3.4. Conclusions
A validated LC–MS/MS method for stability indicating assay
of ZTP was developed. The degradation behavior of the drug
was investigated under hydrolysis (acid, base and neutral),
oxidation, photolysis and thermal stress conditions. The drug
was found to be stable in basic, neutral conditions and unstable
in oxidative conditions. The DPs were identiﬁed by [M+H]+
ion and the proposed structures were supported by LC–MS/MS
experiments combined with accurate mass measurements. The
RP–HPLC method was validated as per ICH guidelines and
ﬁnally applied to the marketed formulations.Acknowledgments
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